drug nanocrystals: novel technique for delivery of ... - Ijsidonline.info

Sneha V Sawant et al., IJSID 2011, 1 (3), 1-15products exploited use different features of the nanocrystals, an overview of market products is given in Examplesof nanocrystal products on the market in Table1.LIMITATIONS OF DRUG NANOCRYSTAL TECHNOLOGYHigh cost instruments required for the production of drug nanocrystal that increases the cost of dosageforms.This technique is limited to BCS class II drug only. Formation of nanocrystal and their stability depend onmolecular structure of drug so only certain class of compounds will qualify. [44]CONCLUSIONPoor aqueous solubility is rapidly becoming the leading hurdle for formulation scientists workingon oral delivery of drug compounds and leads to employment of novel formulation technologies. The use of drugnanocrystals is a universal formulation approach to increase the therapeutic performance of these drugs in anyroute of administration. Almost any drug can be reduced in size to the nanometer range. Owing to their greatformulation versatility drug nanocrystals are no longer only the last chance rescue for a few drugs. Many insolubledrug candidates are in clinical trials formulated as drug nanocrystals. Currently, attention is turned to improvingthe diminution performance to produce drug nanocrystals well below 100 nm, also incases of very hard drugs.First approaches were already successful. New technologies are in development to produce final dosage forms withhigher drug loadings, better redispersability at their site of action, and an improved drug targeting.REFERENCES1. Lipinski C, Poor aqueous solubility— an industry wide problem in drug discovery, Am.Pharm. Rev.2002; 5: 82–85.2. Keck C, Kobierski S, Mauludin R, Müller RH, Second generation of drug nanocrystals for delivery of poorly soluble drugs:smartcrystals technology,D O S I S,2008; 24(2):125-127.3. Troester F, Cremophor-free aqueous paclitaxel nanosuspension—production and chemical stability, Controlled ReleaseSociety 31st annual meeting, Honolulu, HI, 2004.4. Möschwitzer J, Achleitner G, Pomper H, Muller RH, Development of an intravenously injectable chemically stable aqueousomeprazole formulation using nanosuspension technology, European Journal of Pharmaceutics and Biopharmaceutics,2004; 58(3):615–619.5. Noyes A, Whitney W, The rate of solution of solid substances in their own solutions, J Am Soc,1987;19:930-934.6. Mosharraf M, Nystrom C, The effect of particle size and shape on the surface specific dissolution rate of micronizedpractically insoluble drugs, Int J Pharm, 1995; 122: 35-47.7. Rawat N, Senthil M, Solubility: Particle Size Reduction is a Promising Approach to Improve The Bioavailability ofLipophillic Drugs, International Journal of Recent Advances in Pharmaceutical Research, 2011; 1: 8-18.8. Ruddy SB, Ryde NP, inventors; Elan PharmaInternational Limited, assignee, Solid dose nanoparticulate compositions, WO666, 539 , March 28,2002.9. JunghannsJUAH, Muller AH, Nanocrystal technology, drug delivery and clinical Applications, Int J Nanomedicine, 2008;3(3):295–309.10. Gulsan T, Gursoy RN, Oner L, Nanocrystal Technology For Oral Delivery of Poorly Water-Soluble Drugs, J. Pharm. Sci, 2009;34: 55–65.International Journal of Science Innovations and Discoveries, Volume 1, Issue 3, November-Deceber 201113